Alnylam Pharmaceuticals Reports Q3 2026 Earnings and Pipeline Updates

Executive Summary

On October 29, 2026, Alnylam Pharmaceuticals, Inc. filed a Current Report on Form 8-K under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits), announcing its consolidated financial results for the third quarter ended September 30, 2026.

Key Financial Highlights

• Total Revenues: $1,458.1 million for Q3 2026, up 17% from $1,249.0 million in Q3 2025.
• Net Product Revenues:
  • TTR Franchise: Totaled $1,150.0 million (+59% YoY), led by AMVUTTRA at $1,130.4 million (+65% YoY) and ONPATTRO at $19.6 million (-50% YoY).
  • Rare Disease Franchise: Totaled $142.0 million (+12% YoY), with GIVLAARI at $89.5 million (+21% YoY) and OXLUMO at $52.5 million (-1% YoY).
• Operating Income: GAAP income from operations was $345.8 million compared to $368.0 million in Q3 2025; non-GAAP operating income was $424.9 million compared to $476.2 million in Q3 2025.
• Net Income: GAAP net income was $2,167.3 million ($15.72 per diluted share), driven by non-operating/collaboration items, compared to $292.7 million ($2.14 per diluted share) in Q3 2025.

Pipeline and Business Updates

• Nucresiran (TRITON-CM): Expanded target Phase 3 study enrollment from 1,750 to ~2,250 patients; launch expected by 2030.
• Brezosiran (ALN-HTT02): Reported Phase 1 data in Huntington's disease showing 60–64% mean reduction of CSF mHTT; pivotal study planned for 2027.
• Guidance: Reaffirmed that the company remains on track to achieve full-year 2026 financial guidance.